Synageva BioPharma has a market cap of $1.19 billion and an enterprise value of $943 million. This stock trades at a premium valuation, with a price-to-sales of 100.66 and a price-to-book of 4.84. Its estimated growth rate for this year is 78.6%, and for next year it's pegged at -46.7%. This is a cash-rich company, since the total cash position on its balance sheet is $233.41 million and its total debt is zero.
A director and beneficial owner just
bought 859,720 shares, or about $40.86 million worth of stock, at $47.53 per share.
From a technical perspective, GEVA is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has just started to bounce right above its 50-day moving average of $46.93 a share. That move is quickly pushing shares of GEVA within range of triggering a major breakout trade.
If you're in the bull camp on GEVA, then I would look for long-biased if this stock manages to break out above some near-term overhead resistance levels at $51.90 to $52.75 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 137,157 shares. If that breakout triggers soon, then GEVA will set up to re-test or possibly take out its next major overhead resistance levels at $56 to $58 a share. Keep in mind that any move above $58 would then push GEVA into new 52-week high territory, which is bullish technical price action.
One name in the biopharmaceutical complex that insiders are warming up to here is
(OMER - Get Report)
. This company is engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Insiders are buying this stock into extreme weakness, since shares are off by 36% in the last six months.
Omeros has a market cap of $165 million and an enterprise value of $146 million. This stock trades at a premium valuation, with a price-to-sales of 28.98. Its estimated growth rate for this year is -22.5%, and for next year it's pegged at 22.2%. This is a cash-rich company, since the total cash position on its balance sheet is $30.63 million and its total debt is $15.05 million.